Abstract
Cervical cancer (CC) contributes to 6%-29% of all cancers in women. In India, 527,624 new cases of CC are added every year. India contributes to ¼ of deaths worldwide to CC it occurs often in women around the age of 30 yrs which is contributed by a specific kind of human papillomavirus causes long-term infection and inflammation (HPV) which result in morphological changes in the cells of cervix the region that connect vagina and uterus. Cervicovaginal microbiome is observed to be highly diverse among patients with CC where there is reduced number of Latobacillus spp that leads to dysbiosis and decrease in pH and eventually colonised by other anaerobic bacteria. The shift in community state types (CST) is highly associated with the Human Papillomavirus infection and its further progression to cervical dysplasia or CIN i.e. ‘Cervical intraepithelial neoplasia’ and malignant tumour of the cervix uteri. The purpose of this research is to figure out if there’s a link between the cervico-vaginal microbiota and gynaecological cancer and the review also focuses whether cervical microbiome signatures can predict the severity of infection leading to development of CC? Probiotics can be used as a potential alternative to balance the dysbiosis of the cervicovaginal environment. Hence the review summarizes the current knowledge and the interaction of different bacterial groups with Human Papilloma Virus infection and development of CC.
Publisher
Journal of Pure and Applied Microbiology
Subject
Applied Microbiology and Biotechnology,Microbiology,Biotechnology
Reference57 articles.
1. 1. Small W, Bacon MA, Bajaj A, et al. Cervical cancer: A global health crisis: Cervical Cancer: A Global Health Crisis. Cancer. 2017;123(13):2404-2412. doi: 10.1002/cncr.30667
2. 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492
3. 3. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89(1):101-105. doi: 10.1038/sj.bjc.6601024
4. 4. Braaten KP, Laufer MR. Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine. Rev Obstet Gynecol. 2008;1(1):2-10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2492590/. Accessed July 3, 2021.
5. 5. Shulzhenko N, Lyng H, Sanson GF, Morgun A. Menage a trois: an evolutionary interplay between human papillomavirus, a tumor, and a woman. Trends Microbiol. 2014;22(6):345-353. doi: 10.1016/j.tim.2014.02.009